Using the Multiphase Optimization Strategy (MOST) to optimize an HIV care continuum intervention for vulnerable populations : a study protocol by Gwadz, Marya Viorst et al.
BMC Public Health
 
Using the Multiphase Optimization Strategy (MOST) to optimize an HIV care continuum
intervention for vulnerable populations: A study protocol
--Manuscript Draft--
 
Manuscript Number:
Full Title: Using the Multiphase Optimization Strategy (MOST) to optimize an HIV care continuum
intervention for vulnerable populations: A study protocol
Article Type: Study protocol
Section/Category: Health behaviour, health promotion and society
Funding Information: National Institute on Drug Abuse
(R01DA040480)
Dr. Marya Viorst Gwadz
Abstract: Abstract
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insufficiently engaged in HIV primary care and not taking antiretroviral therapy (ART),
mainly African Americans/Blacks and Hispanics. In the proposed project, a potent and
innovative research methodology, the multiphase optimization strategy (MOST), will be
employed to develop a highly efficacious, efficient, scalable, and cost-effective
intervention to increase engagement along the HIV care continuum. Whereas
randomized controlled trials are valuable for evaluating the efficacy of multi-component
interventions as a package, they are not designed to evaluate which specific
components contribute to efficacy. MOST, a pioneering, engineering-inspired
framework, addresses this problem through highly efficient randomized
experimentation to assess the performance of individual intervention components and
their interactions. We propose to use MOST to engineer an intervention to increase
engagement along the HIV care continuum for African American/Black and Hispanic
PLWH not well engaged in care and not taking ART. Further, the intervention will be
optimized for cost-effectiveness. A similar set of multi-level factors impede both HIV
care and ART initiation for African American/Black and Hispanic PLWH, primary
among them individual- (e.g., substance use, distrust, fear), social- (e.g., stigma), and
structural-level barriers (e.g., difficulties accessing ancillary services). Guided by a
multi-level social cognitive theory, the study will evaluate five distinct intervention
components (i.e., Motivational Interviewing counseling sessions, pre-adherence
preparation, support groups, peer mentorship, and patient navigation), each designed
to address a specific barrier to HIV care and ART initiation. These components are
well-grounded in the empirical literature and were found acceptable, feasible, and
promising with respect to efficacy in a preliminary study.
Methods/design. Study aims are: 1) using a highly efficient fractional factorial
experimental design, identify which of five intervention components contribute
meaningfully to improvement in HIV viral suppression, and secondary outcomes of
ART adherence and engagement in HIV primary care; 2) identify mediators and
moderators of intervention component efficacy; and 3) using a mathematical modeling
approach, build the most cost-effective and efficient intervention package from the
efficacious components. A heterogeneous sample of African American/Black and
Hispanic PLWH (with respect to age, substance use, and sexual minority status) will be
recruited with a proven hybrid sampling method using targeted sampling in community
settings and peer recruitment (N=512).
Discussion. This is the first study to apply the MOST framework in the field of HIV
prevention and treatment. This innovative study will produce an HIV care continuum
intervention for the nation's most vulnerable PLWH, optimized for cost-effectiveness,
and with exceptional levels of efficacy, efficiency, and scalability.
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Abstract 27 
Background. More than half of persons living with HIV (PLWH) in the United States are 28 
insufficiently engaged in HIV primary care and not taking antiretroviral therapy (ART), 29 
mainly African Americans/Blacks and Hispanics. In the proposed project, a potent and 30 
innovative research methodology, the multiphase optimization strategy (MOST), will be 31 
employed to develop a highly efficacious, efficient, scalable, and cost-effective 32 
intervention to increase engagement along the HIV care continuum. Whereas 33 
randomized controlled trials are valuable for evaluating the efficacy of multi-component 34 
interventions as a package, they are not designed to evaluate which specific 35 
components contribute to efficacy. MOST, a pioneering, engineering-inspired framework, 36 
addresses this problem through highly efficient randomized experimentation to assess 37 
the performance of individual intervention components and their interactions. We 38 
propose to use MOST to engineer an intervention to increase engagement along the HIV 39 
care continuum for African American/Black and Hispanic PLWH not well engaged in care 40 
and not taking ART.  Further, the intervention will be optimized for cost-effectiveness. A 41 
similar set of multi-level factors impede both HIV care and ART initiation for African 42 
American/Black and Hispanic PLWH, primary among them individual- (e.g., substance 43 
use, distrust, fear), social- (e.g., stigma), and structural-level barriers (e.g., difficulties 44 
accessing ancillary services). Guided by a multi-level social cognitive theory, the study 45 
will evaluate five distinct intervention components (i.e., Motivational Interviewing 46 
counseling sessions, pre-adherence preparation, support groups, peer mentorship, and 47 
patient navigation), each designed to address a specific barrier to HIV care and ART 48 
initiation. These components are well-grounded in the empirical literature and were 49 
found acceptable, feasible, and promising with respect to efficacy in a preliminary study.  50 
 51 
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Methods/design. Study aims are: 1) using a highly efficient fractional factorial 52 
experimental design, identify which of five intervention components contribute 53 
meaningfully to improvement in HIV viral suppression, and secondary outcomes of ART 54 
adherence and engagement in HIV primary care; 2) identify mediators and moderators 55 
of intervention component efficacy; and 3) using a mathematical modeling approach, 56 
build the most cost-effective and efficient intervention package from the efficacious 57 
components. A heterogeneous sample of African American/Black and Hispanic PLWH 58 
(with respect to age, substance use, and sexual minority status) will be recruited with a 59 
proven hybrid sampling method using targeted sampling in community settings and peer 60 
recruitment (N=512).  61 
 62 
Discussion. This is the first study to apply the MOST framework in the field of HIV 63 
prevention and treatment. This innovative study will produce an HIV care continuum 64 
intervention for the nation’s most vulnerable PLWH, optimized for cost-effectiveness, 65 
and with exceptional levels of efficacy, efficiency, and scalability. 66 
 67 
Trial Registration. ClinicalTrials.gov, NCT02801747, Registered June 8, 2016 68 
 69 
Keywords: HIV care continuum; antiretroviral initiation; HIV care; multiphase 70 
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Background 73 
Even with recent important advances in the efficacy and tolerability of HIV treatment [1-74 
6], serious gaps persist in the HIV care continuum in the United States [7, 8]. The 75 
Centers for Disease Control and Prevention estimates that of 1.2 million Americans 76 
living with HIV, 60% are not retained in HIV care; 63% are not taking antiretroviral 77 
therapy (ART); and 70% have detectable HIV viral load (VL) [9]. Poor engagement along 78 
the HIV care continuum increases risk for morbidity and early mortality [10-12], 79 
hospitalizations and increased health care costs [13, 14], and risk of forward 80 
transmission of HIV. Indeed, poor retention in HIV primary care is a principal cause of 81 
HIV/AIDS-related mortality [15-18], and lack of ART initiation further places persons 82 
living with HIV (PLWH) at elevated risk for substandard CD4 and VL outcomes [11, 19, 83 
20]. 84 
 85 
Because most PLWH are African American/Black or Hispanic [21], gaps in engagement 86 
along the HIV care continuum are concentrated among these populations. Moreover, 87 
compared to their White peers, African American/Black and Hispanic PLWH (AABH-88 
PLWH) are more likely to be diagnosed late in the course of their HIV disease, delay 89 
uptake of ART, discontinue ART, and to have higher rates of morbidity and earlier 90 
mortality from HIV [22-25]. Further, these racial/ethnic disparities are found among all 91 
major risk categories; namely, persons who inject drugs (PWID), men who have sex with 92 
men (MSM), and heterosexuals [26, 27]. The Centers for Disease Control and 93 
Prevention, Office of AIDS Research [28], and National HIV/AIDS Strategy [29] have 94 
stressed the importance of eliminating racial/ethnic disparities in HIV health outcomes, 95 
thereby signaling the need for culturally targeted HIV care continuum interventions [29-96 
31]. 97 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
5 
 
 98 
The MOST framework 99 
The primary goal of the present study is to use the innovative multiphase optimization 100 
strategy (MOST) to select individual intervention components to comprise an optimized 101 
behavioral intervention, where the optimized intervention is the one that provides the 102 
greatest improvement in health outcomes achievable within the specified resource 103 
constraints [32]. MOST is an engineering-inspired framework and systematic method for 104 
identifying the optimized combination of intervention components before testing an 105 
intervention in a resource-intensive randomized controlled trial (RCT). MOST consists of  106 
three stages: 1) preparation, 2) optimization, and 3) evaluation of the optimized 107 
intervention in an RCT [32]. While the RCT is an excellent approach for evaluation of an 108 
intervention package as a whole, it was never intended to provide information about the 109 
performance of the individual components making up the intervention package. By 110 
contrast, MOST calls for empirically examining the efficacy of each separate intervention 111 
component, along with its resource requirements and costs.  112 
 113 
Objectives of the present study 114 
In the present study, the goal is to select the set of intervention components likely to 115 
improve health outcomes to the greatest extent per dollar spent, yielding a cost-effective, 116 
efficient, and scalable culturally appropriate behavioral intervention for AABH-PLWH. In 117 
recent preliminary research, we identified a set of promising intervention components for 118 
AABH-PLWH not taking ART and poorly engaged in HIV care [33, 34]. In the present 119 
study, an innovative and economical fractional factorial experimental design will be used 120 
to examine the effects of a set of five individual intervention components, their 121 
interactions, as well as mediation and moderation effects for each individual intervention 122 
component, providing a detailed look at the mechanisms by which each component 123 
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works. Then, in the optimization process, based on modeling analyses, we will identify 124 
the combination of intervention components (likely 2-3 components) with the greatest 125 
levels of efficacy and cost-effectiveness, eliminating poorly performing, costly, or 126 
ineffective components, called the “optimized intervention” [35-37]. The optimized 127 
intervention developed using this powerful new approach has the potential to make a 128 
major impact on engagement in HIV care and uptake of ART among AABH-PLWH, 129 
improving the health of this population, reducing forward transmission of HIV, and 130 
decreasing racial/ethnic HIV disparities – all national priorities [28, 29, 38, 39]. This 131 
project will be the first application of the MOST framework in the field of HIV prevention 132 
and treatment, and will result in the first optimized intervention aimed at improving 133 
engagement along the HIV continuum of care using biological outcomes (namely, CD4 134 
and VL levels). 135 
 136 
Aims of the study 137 
Thus the aims of the present study are:  138 
 139 
Aim 1: Using a highly efficient experimental design, identify which of five components 140 
contribute meaningfully to improvement in the primary outcome, HIV viral suppression, 141 
and secondary outcomes, absolute HIV viral load, ART adherence, and engagement in 142 
HIV primary care, all assessed via objective biomarkers or through the medical record. 143 
 144 
Aim 2: Identify mediators and moderators of the efficacy of each intervention component 145 
(e.g., substance use history, sexual minority status), and also of interaction effects 146 
between components. 147 
 148 
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Aim 3: Using a mathematical modeling approach, build the most cost-effective and 149 
efficient intervention package from the components found to be efficacious in Aim 1. 150 
 151 
Methods/Design 152 
Overview of the study 153 
The present study focuses on African American/Black and Hispanic PLWH not well 154 
engaged in HIV care nor taking ART, referred to as “PLWH-NECTA”. We will enroll a 155 
heterogeneous sample of PLWH-NECTA (with respect to age, substance use, mental 156 
health, and sexual minority status). PLWH-NECTA are not typically found in HIV clinics. 157 
Instead, participants (N=512) will be recruited with a proven hybrid sampling method 158 
using targeted sampling and peer recruitment, described below [33]. The present study 159 
is comprised of three stages: (1) Refinement (6 months); (2) Implementation, Cost 160 
Effectiveness Analysis, and Optimization (48 months); and (3) Final (6 months). 161 
Intervention optimization in stage 2 will proceed as follows: Five promising individual 162 
intervention components will be examined by means of a fractional factorial experiment. 163 
The five intervention components, described in detail below, are: (A) Motivational 164 
Interviewing (MI) counseling sessions; (B) Pre-adherence preparation; (C) Peer 165 
mentorship; (D) Focused support groups; and (E) Navigation. Each component 166 
addresses one theoretical mediator or one small set of theoretical mediator(s) linked to 167 
known barriers to good engagement in HIV care and ART uptake among PLWH-NECTA, 168 
as shown in the study’s conceptual model (Figure 1), and described below. All 169 
participants will receive a Core intervention session and be randomly assigned to one of 170 
16 experimental conditions. Time and cost expenditure data for each intervention 171 
component will be collected. Then, mathematical modeling based on the results of the 172 
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experiment will determine the most efficacious and cost-effective combination of 173 
intervention components, eliminating ineffective components. 174 
(insert Figure 1. Conceptual model grounded in the Theory of Triadic Influence and 175 
Self Determination Theory) 176 
 177 
Theoretical model 178 
The present study is guided by a theoretical model incorporating the Theory of Triadic 179 
Influence [40] and Self Determination Theory [41, 42]. The Theory of Triadic Influence is 180 
a multi-level social-cognitive theory articulating three “streams of influence” acting 181 
simultaneously on health behavior; namely, the individual, social, and structural. 182 
Complementing the Theory of Triadic Influence, Self Determination Theory highlights the 183 
importance of durable, high-quality, intrinsic motivation for behavior change [41, 42]. The 184 
integrated theoretical model assumes the lack of HIV care and ART initiation are not 185 
independent: those who fear or otherwise decline ART present less frequently for HIV 186 
care [43, 44], and those not well engaged in HIV care rarely gain access to ART [21]. 187 
Importantly, these two gaps in the HIV care continuum – poor engagement in HIV care 188 
and low uptake of ART - are largely driven by the same set of multi-level risk factors and 189 
barriers [33, 34]. Guided by this integrated theoretical model, we next describe the 190 
primary barriers AABH-PLWH experience to both HIV care and ART initiation with 191 
sustained good adherence [45-47]. 192 
 193 
Description of barriers to HIV care and ART  194 
At the individual level of influence primary barriers to HIV care/ART for AABH-PLWH 195 
include negative health beliefs such as medical distrust, negative outcome expectancies, 196 
low levels of “readiness” [48-52], and negative emotions about care/ART, including fear 197 
[53-55]. Indeed, the primacy of fear as a barrier; namely, fear of being pressured to take 198 
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ART in health care settings, of ART’s side effects and toxicities, and possible negative 199 
effects on relationships if on ART, cannot be over-stated [56, 57]. Substance use is 200 
another common barrier [33, 58-61], as are mental health concerns, primarily depression 201 
[62-65]. Further, lack of knowledge about care/ART guidelines [48, 66, 67] impedes 202 
ART/care, and PLWH often decline ART because they lack behavior skills to maintain 203 
adherence to ART [68, 69]. 204 
 205 
Barriers at the social level of influence include a lack of positive “successful” peer role 206 
models who are regularly engaged in HIV care and taking ART with good adherence, 207 
who can challenge prevalent social/peer norms that health care systems cannot be 208 
trusted and ART is toxic and should be avoided [43, 44, 46]. Social isolation and low 209 
levels of social support also impede HIV care and ART use [70, 71], as does HIV stigma, 210 
compounded by stigma associated with poverty, substance use, and/or sexual minority 211 
status [72-74]. 212 
 213 
At the structural level of influence, barriers include challenges negotiating the health care 214 
system, including relations with providers [75, 76], transportation problems, and access 215 
to care for substance use and mental health concerns, as well as HIV [44, 48, 77]. 216 
Interventions may not eliminate structural barriers, but can reduce their effects by 217 
increasing participants’ options [78]. Barriers at all three levels are commonly rooted in 218 
poverty [44, 77, 79, 80] and combine synergistically to reduce AABH-PLWH’s motivation, 219 
behavioral skills, and access to HIV care and ART. On the other hand, factors facilitating 220 
good health outcomes operate concurrently with barriers, including intrinsic motivation to 221 
achieve good health [44, 81-84] and supportive network members [85]. As shown in 222 
Figure 1, and described in more detail below, the present study will test a set of 223 
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intervention components designed to address the primary barriers AABH-PLWH 224 
experience to HIV care and ART initiation at these three levels of influence. 225 
 226 
The present study attends to the needs of MSM  227 
African American/Black and Hispanic MSM are greatly over-represented among the 228 
population of PLWH, making up more than half of the population of PLWH nationally 229 
[86]. Similar to other subgroups of AABH-PLWH, African American/Black and Hispanic 230 
MSM have suboptimal rates of linkage to care, retention in care, ART initiation, and HIV 231 
viral suppression [30]. Prior epidemiologic research highlights a number of clinical and 232 
socio-structural factors that create barriers to engagement along the HIV care continuum 233 
for African American/Black and Hispanic MSM. These include stigma related to HIV, as 234 
well as to sexual minority status, substance use, stress, and depression [72, 87-90]. The 235 
present study includes a focus on this critical subpopulation of PLWH. We estimate 55-236 
60% of males in the present study will be MSM [33, 34].  237 
 238 
The present study addresses substance use and mental health concerns  239 
Drug and alcohol use, and substance use problems, are endemic among PLWH [59, 60] 240 
and serve as major barriers to engagement along the HIV care continuum [59-61, 91, 241 
92]. Cocaine, marijuana, opioids, and alcohol are the most frequently used substances, 242 
and poly-substance use is common [59, 92]. While recent injection drug use is not highly 243 
prevalent in this population (<4%) [60, 92], lifetime injection drug use prevalence is 244 
substantial (~17%) and associated with poor HIV outcomes [62], including delayed HIV 245 
diagnosis, reduced entry into and retention in HIV care, delayed initiation of ART, inferior 246 
adherence to ART [93, 94], and poor treatment outcomes [59]. Yet substance use does 247 
not preclude engagement in HIV care and good ART adherence [95], and substance use 248 
problems, while they may be serious, are addressable. Among PWID, opioid substitution 249 
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therapy is associated with better adherence to ART [95-98], and a number of promising 250 
behavioral interventions have been developed for substance users living with HIV [97, 251 
99-101]. Given the critical role substance use plays in HIV disparities, intervention efforts 252 
for HIV-infected substance users are vital [102]. Based on our own research [33, 74] and 253 
on national data [92], we estimate 55% of participants in the present study will be current 254 
substance users, primarily non-injectors, 25% will be past users (including PWID), and 255 
20% will be non-users. Relatedly, mental health problems are widespread among AABH-256 
PLWH, mainly depression and anxiety. We estimate 60-65% of the sample in the 257 
present study will evidence mental health distress at clinically significant levels [33, 34].  258 
 259 
Explanation for the choice of intervention components to be tested 260 
The intervention components to be evaluated in the present study were developed and 261 
tested as a packaged intervention in a previous intervention development RCT. The 262 
intervention, called “Heart to Heart” (HTH), was highly efficacious, producing substantial 263 
reductions in VL, the study’s primary outcome, assessed via the medical record. Further, 264 
the intervention was highly acceptable and feasible, including for substance users, 265 
sexual minorities, and both males and females, and retention was excellent (> 95% 266 
attended the intervention; 90% completed a 4-month follow up assessment and 80% 267 
complete the 8-month follow up assessment) [34]. Rates of ART initiation were similar 268 
across arms (~ 58%) but 8 months post-baseline, participants in the intervention arm 269 
were three times more likely to evidence “good” (that is, 7 day/week) adherence (60% 270 
vs. 26.7%; p=0.087; OR=3.95), as assessed via ART concentrations in hair samples 271 
[103], and had significantly lower VL (intervention log10 VL= 1.63 [SD=0.67], controls 272 
2.51 [SD=1.55], OR=3.70; p=0.02) than controls based on medical records.  273 
 274 
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Findings from the HTH study as well as the larger empirical literature on interventions for 275 
PLWH formed the basis for the selection of individual intervention components to be 276 
tested in the present study. We used the following guidelines for selecting components. 277 
Each component must: address one or one small set of theoretical mediator(s); be 278 
distinct from the others in content, length, delivery method, and/or approach; have, at 279 
minimum, preliminary evidence of efficacy or promise in the empirical literature; have 280 
been found feasible for and acceptable to the population under study; not require that 281 
any other component be administered along with it in order to be efficacious; and be 282 
guided by a detailed manual. We formed an Intervention Working Group, led by Dr. 283 
Gwadz, the PI of the HTH study and Co-PI of the present study (with Dr. Linda Collins). 284 
The Intervention Working Group was made up of senior research scientists expert in 285 
AABH-PLWH, members of the target population, and experienced clinical 286 
interventionists, who applied these criteria in an iterative process using Intervention 287 
Mapping, to select the most promising components. 288 
 289 
Description of intervention components to be tested 290 
The Intervention Working Group identified five discrete intervention components for 291 
inclusion, as well as a preparatory Core intervention session to be conducted with all 292 
participants. Each component has two “levels” to be compared in the fractional factorial 293 
design: either yes/provided vs. no/not provided (Components A-D), or short version vs. 294 
long version (Component E). The five components selected for study are described 295 
below. The present study will be a definitive test of the efficacy of each component 296 
selected. Components will be guided by detailed manuals and will be culturally 297 
appropriate. Further, components will be individually tailored on substance use, mental 298 
health problems, and sexual minority status; manualized “algorithms” will be used to 299 
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query or provide feedback (from baseline data) on these indices, followed by a series of 300 
prompts to guide the individually tailoring.  301 
Core intervention session (~60 minutes). All participants will receive a 302 
foundational Core intervention session. The goals of this component are to: 1) foster 303 
engagement and build trust/relationships and 2) provide standard treatment education 304 
on the current U.S. Department of Health and Human Services recommendations for 305 
frequency of HIV care appointments and timing of ART initiation [104, 105]. The primary 306 
theoretical target is HIV treatment knowledge. 307 
Component A: MI Counseling sessions, ~60-90 minutes each, 4 sessions. 308 
Sessions will be conducted with participants individually and made up of discrete 309 
exercises. Each session will include 1-2 culturally targeted video narrative segments to 310 
highlight key issues and foster discussion [106, 107]. Session 1 addresses barriers to 311 
HIV care. Sessions 2 and 3 target barriers to ART (S2: evoking barriers, fostering 312 
readiness; S3: decisions, plans). Session 4 addresses adherence, individual barriers 313 
and their solutions in depth, and finalizing care/ART plans. This component’s primary 314 
theoretical targets are health beliefs (e.g., outcome expectancies, self-efficacy, medical 315 
distrust), and emotions (e.g., concerns/fears of ART). 316 
Component B: Pre-adherence preparation (2-6 wk. period). The Health 317 
Resources and Services Administration (HRSA) provides guidelines for preparing 318 
PLWH-NECTA for treatment success [108-110], an approach supported by the research 319 
literature [69, 105, 110-112]. Component B is grounded in the HRSA guidelines. Its 320 
goals are to prepare the physical and social “adherence environment,” put long-term 321 
ART supports in place, and build adherence skills. Component B is flexible and 322 
individualized and will first entail an in-person orientation home session (< 90 min) to 323 
assess readiness for ART, identify individual barriers to adherence prior to initiating ART 324 
(e.g., substance use), link adherence to daily activities to build habits, put educational 325 
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and visual aids and reminders in place, understand side effects, identify and involve 326 
long-term supports/supporters who can reinforce successes, and plans to minimize 327 
lapses if doses are missed. With the participant’s consent, the health care provider will 328 
be queried regarding the simplest dosing schedule [108, 113]. Next, a series of trial runs, 329 
with feedback, will be conducted (1-4 week-long trials). Trial runs will comprise 1-week 330 
practice trials with a daily pill regimen similar to the actual future ART regimen (obtained 331 
from providers, if possible) but using vitamins. Adherence to vitamins will be monitored 332 
with medication event monitoring system (MEMS) caps or a similar electronic adherence 333 
monitoring device, to help participants work toward a goal of > 85% adherence [114]. 334 
After each week-long trial, participants will receive feedback from the study 335 
interventionist on their adherence patterns, a key strategy to boost motivation [84], and 336 
barriers of/facilitators to adherence, if any, will be explored. Participants will make a 337 
personal decision about ART initiation with their providers; those with < 85% adherence 338 
will not be discouraged initiating ART. This component’s primary theoretical target is 339 
behavioral skill to manage ART adherence. 340 
Component C: Peer mentorship (regular interactions with a highly trained 341 
“successful” peer mentor [4 months]). Linking PLWH with peer mentors is an 342 
efficacious approach to HIV-related behavior change [15, 115-121]. Successful peer 343 
mentors (i.e., demographically similar PLWH who have consistently engaged in care and 344 
are taking ART with good adherence) can serve as credible role models and challenge 345 
negative peer norms about HIV care and ART [15, 115, 118]. The training curriculum for 346 
and core elements of Component C are based on the HRSA-funded Peer Education & 347 
Evaluation Resource (PEER) model [122]. Meeting approximately weekly face-to-face or 348 
by phone, the role of the peer mentor will be to: provide informal counseling; model 349 
healthy HIV behavior; provide practical tips for managing care/ART based on his/her 350 
personal experience; and provide resources to address barriers to care/ART [122, 123]. 351 
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This component’s primary theoretical targets are peer modeling and peer norms. 352 
Secondary theoretical targets are social support and stigma. 353 
Component D: Focused support groups (6 groups, ~90 mins. each, every 2-354 
3 weeks over 4 months). Support groups can address the social isolation and stigma 355 
endemic among PLWH-NECTA [124-131]. Component D aims to provide emotional and 356 
instrumental support, reduce stigma, give acceptance or validation, and encourage shifts 357 
in perspective [132, 133]. Groups will be guided by the MI approach, facilitated by a 358 
skilled interventionist, focus on barriers to and decisions regarding care/ART, provide 359 
general social support, and attend to issues MSM, substance users, and those with 360 
mental health concerns face [134]. This component’s primary theoretical targets are 361 
social support and stigma regarding care/ART status. This is the only intervention 362 
component where participants from the different experimental conditions will engage 363 
with each other, raising the possibility of contamination among participants. A description 364 
of possible types of contamination and procedures to prevent contamination are 365 
described below.   366 
Component E: Navigation (3 months [short] vs. 6 months [long]). Navigation 367 
is an efficacious, flexible, individualized, strengths-based approach to assist PLWH in 368 
identifying and overcoming barriers to health services [135-139]. Participants will be 369 
randomized to receive a short (3 months) or long (6 months) period of navigation [34, 370 
140]. All participants receive at least the short version of this component because of the 371 
primacy of structural barriers to HIV care and ART, and need for ancillary services 372 
among PLWH-NECTA (e.g., for substance use and mental health), although the optimal 373 
duration of navigation is not known [136, 140]. Component E is based on the HRSA HIV 374 
System Navigation model [136]; delivered by a trained interventionist; menu-based; and 375 
highly focused. Core elements include: an initial face-to-face meeting (< 90 mins.) for 376 
review of participant’s readiness for and barriers to care/ART, including substance use 377 
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and mental health, and creation of a Change Plan/Action Plan, and a minimum of weekly 378 
phone (including text messages), email, and in-person meetings during the navigation 379 
period, depending on need. The menu of activities includes: screening and “Fast Track” 380 
referrals for substance use, mental health, and other problems including MSM-friendly 381 
sites; communication with primary care provider, as needed, about the participant’s 382 
service needs and care/ART plans; and accompaniment to health care appointments. 383 
This component’s primary theoretical target is ameliorating structural barriers to care and 384 
ART. 385 
 386 
Outcomes 387 
Study outcomes will be assessed using objective data. The primary outcome is HIV 388 
virologic suppression analyzed as a dichotomous measure (assessed via lab report). 389 
Secondary outcomes include 1) absolute HIV VL (a continuous measure, assessed via 390 
lab report), 2) adherence to ART as assessed by ART concentrations in hair samples 391 
[103], and 3) engagement in HIV primary care, defined below (assessed via medical 392 
records) [105]. 393 
 394 
Study setting 395 
The study will be located in New York City, which has a large HIV epidemic, with 396 
approximately 115,000 PLWH, >75% African American/Black and Hispanic and ~55% 397 
MSM. Comparable to other urban areas, New York City has a large network of HIV care 398 
settings and all PLWH have access to care and ART [141]. Nonetheless, at the time the 399 
study was planned, New York City data indicated 45% were not retained in care, 49% 400 
were not taking ART, and 59% were not virally suppressed [142]. Thus >50,000 PLWH-401 
NECTA reside in the local area, overwhelmingly African American/Black and Hispanic, 402 
concentrated in geographic areas with elevated rates of poverty [141, 143]. We will 403 
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locate a project field site in one of the geographical areas with high rates of poverty and 404 
prevalent HIV (e.g., in central Brooklyn) and project activities will take place there. 405 
 406 
Trial design 407 
The effects of the five individual components will be examined by means of an 408 
innovative, highly efficient fractional factorial experiment. A factorial experiment is an 409 
efficient way to examine these five components, for two reasons. First, factorial 410 
experiments separate component effects, enabling estimation of the main effect 411 
contribution of each candidate component and interactions between components. 412 
Second, factorial experiments can be economical compared to alternative designs, 413 
because they often require substantially fewer participants to achieve the same 414 
statistical power for component effects [36, 144]. 415 
As noted above, we plan to conduct a fractional factorial experiment involving five 416 
factors, each with two levels. The first four factors are: (A) MI counseling sessions; (B) 417 
Pre-adherence preparation; (C) Peer mentorship; and (D) Focused support groups. For 418 
components A-D, the levels of each of these factors are “no” (not included in the 419 
intervention) and “yes” (included in the intervention). The levels of the fifth factor, (E) 420 
Navigation, are “short duration” navigation (3 months) and “long duration” navigation (6 421 
months).  422 
 423 
Our power analysis, presented below, indicates that N=512 is sufficient to maintain 424 
power of at least 0.8. Conducting five individual experiments, one for each component, 425 
would require N=2,560, or five times as many participants as the factorial experiment, 426 
and comparative, dismantling, and constructive experimental designs would require 427 
N=1,536, or three times as many participants [36]. The fractional factorial design 428 
selected for this study requires 16 experimental conditions. The 16 conditions in the 429 
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design selected for the present study are presented in Figure 2, and procedures used to 430 
select these conditions are described below. 431 
(insert Figure 2. Conditions in the fractional factorial design) 432 
 433 
This design should not be considered a 16-arm RCT. The purpose and logical 434 
underpinnings of the factorial experiment, as well as the logic behind powering factorial 435 
experiments, are different from those of an RCT. The purpose of an RCT is direct 436 
comparison of the efficacy or effectiveness of two or more versions of an intervention. By 437 
contrast, although each of the 16 conditions in Figure 2 represents a viable version of 438 
the enhanced HTH intervention, a factorial design never calls for direct comparison of 439 
these experimental conditions to see which one is best. Instead, the purpose of a 440 
factorial experiment in this context is to identify which components are (a) efficacious 441 
and/or (b) augment the efficacy of other components, so that we can select the ones that 442 
form the most cost-effective intervention. Efficiency comes from basing estimates of all 443 
estimated main effects and interactions on all 16 conditions in the factorial experiment. 444 
For example, the main effect of MI counseling sessions will be estimated by comparing 445 
the mean outcome across Conditions 1-8 vs. the mean outcome across Conditions 9-16. 446 
All participants are included in the estimate of each main effect. This is quite different 447 
from how RCTs are analyzed, and is why factorial experiments can have a relatively 448 
small per-condition sample size and still have excellent power if the total N is sufficient 449 
[36, 144]. The fractional factorial design does not contain a traditional control group; it 450 
does not require one, because individual conditions are never compared [36]. Instead, 451 
each factor has two levels, one of which serves as a control for that factor. 452 
 453 
Other advantages of the factorial experiment include that cost-effectiveness can 454 
supplement efficacy as criteria for determining which components will be included in the 455 
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final optimized intervention, thereby increasing the pre-test likelihood that the MOST-456 
engineered intervention is cost-effective. If a component is efficacious but with a much 457 
higher cost than other components with comparable efficacy, the high-cost component 458 
can be excluded from the final intervention. In addition, the factorial experiment enables 459 
examination of mediators of individual intervention component effects, for a detailed look 460 
at how components operate. It also allows for the examination of and moderator effects. 461 
Regarding moderators, we will conduct exploratory analyses to examine whether 462 
gender, race/ethnicity, substance use patterns, sexual minority status, and other relevant 463 
variables are moderators of component efficacy. This will inform future research aimed 464 
at developing adaptive interventions [145] made of different combinations of components 465 
tailored to respond to individual differences (Aim 2). 466 
 467 
Explanation for choice of experimental conditions 468 
A complete factorial experiment would have 25=32 experimental conditions. To conserve 469 
resources and reduce logistical complexity, we have chosen an innovative 25-1 fractional 470 
factorial design [146] that cuts the number of experimental conditions in half, to 16. A 471 
fractional factorial design is made up of a strategically selected subset of the 472 
experimental conditions required in a complete factorial design. These 16 conditions 473 
were selected based solely on statistical considerations [36]. We used PROC FACTEX 474 
in SAS to select the design presented in Figure 2 [147]. These 16 conditions included in 475 
the fractional factorial design are based on prioritizing estimation of intervention 476 
component main effects and two-way interactions. 477 
 478 
The tradeoff for the economy gained by using a fractional factorial design is that some 479 
effects become entangled or “aliased.” The fundamental principle underlying fractional 480 
factorial designs is to construct a study so the effects of primary interest are aliased with 481 
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effects not expected to be large or important, typically higher-order interactions. In our 482 
design, each main effect is aliased with a four-way interaction, and each two-way 483 
interaction is aliased with a three-way interaction. Because our theoretical model 484 
(presented in Figure 1) does not specify any sizeable three-way or four-way interactions, 485 
we find this aliasing of effects an acceptable price to pay for a dramatic reduction in 486 
research implementation costs. 487 
 488 
Recruitment 489 
The sampling plan is based on a proven efficient strategy [33]. PLWH-NECTA, even 490 
those out of care, tend to be networked with other PLWH through HIV and general social 491 
service and substance use settings [7, 148-150], and through MSM social, drug use, and 492 
sexual networks [151, 152], although a minority are not networked [67]. The sampling 493 
plan, a hybrid recruitment strategy, is informed by literature on recruiting hard-to-reach 494 
populations, which calls for extended timeframes, appropriate resourcing costs, 495 
formative research, and community partnerships [153-155]. The sampling plan has three 496 
main elements: identification of diverse venues where PLWH-NECTA can be located by 497 
professional and peer experts, targeted sampling by staff/peer recruiter teams, and peer-498 
to-peer recruitment. Specifically, a Community Advisory Board (CAB) comprised of local 499 
experts and “successful” members of the target population (former PLWH-NECTAs) will 500 
meet bi-monthly. This CAB will identify diverse recruitment venues. The hybrid sampling 501 
plan will entail regular targeted sampling events conducted by staff and former PLWH-502 
NECTA from these organizations. Peer-to-peer recruitment [106] will begin with a small 503 
number of “initial seeds” (N=5-15) drawn from the targeted sampling venues and the 504 
CAB. Seeds will be given 3-8 coded recruitment coupons and will be asked to recruit 505 
peers (whom they know by name or face, are living with HIV, and they believe/suspect 506 
are not engaged in care and/or on ART) for which they will receive modest 507 
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compensation ($10/peer) [106]. Peers will be screened for eligibility and then have the 508 
opportunity to recruit other peers until sample size goals are met. Sampling will take 509 
place in study months 7 to 33 (27 months, 19 participants/month). 510 
 511 
Eligibility criteria 512 
Eligibility criteria include: 1) age 18 – 65 years; 2) African American/Black or Hispanic 513 
race/ethnicity; 3) HIV diagnosed for at least 6 months (HIV status confirmed with medical 514 
documentation); 4) has not taken ART in the past 6 weeks (the period of time assessed 515 
by a hair assay, described below, and a reasonable period of time not on ART for the 516 
present study); 5) sub-optimal engagement in HIV care (assessed from the medical 517 
record, defined as less than 1 visit in every 4-month period in the past year [two of them 518 
at least 90 days apart], pro-rated for those diagnosed less than a year ago) or > 2 519 
missed visits (without prior cancellation) in the past year [156]; 6) reside in the New York 520 
City metropolitan area; 7) not planning to leave the New York City metropolitan area in 521 
next year; 8) not actively psychotic based on screening instrument [157]; 9) not a 522 
participant in the preliminary pilot HTH study; 10) able to conduct research activities in 523 
English or Spanish; 11) willing to provide hair sample (if possible), blood samples (to 524 
assess CD4, VL), and a Medical Report Form ([MRF], described below, to assess health 525 
care attendance); 12) willing to participate in a Core intervention session and be 526 
randomly assigned to 1-5 intervention components. 527 
 528 
Participant timeline 529 
An easy-access two-step screening procedure has been designed for efficiency and 530 
ease of completion, while fostering engagement and trust (Figure 3). 531 
(insert Figure 3. Sequence of HTH2-MOST study activities) 532 
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Step 1. First screening interview (by phone) for eligibility. Verbal consent will 533 
be obtained and a structured pre-screening interview will be conducted to preliminarily 534 
screen for eligibility (criteria assessed by self-report). If preliminarily eligible, next steps 535 
to determine eligibility will be explained. 536 
Step 2. Second screening interview for eligibility. Written informed consent 537 
for the remaining screening procedures will be obtained, as well as locator information. 538 
HIV status will be confirmed with medical documentation provided by the participant, 539 
then a hair sample collected to test whether the participant has used ART in the past 6 540 
weeks, and a signed Release Form for Medical Records Office and Health Insurance 541 
Portability and Accountability Act (HIPAA) authorization form for the MRF will be 542 
obtained. Staff will outreach to the Medical Records office to obtain information on 543 
attendance at medical appointments. When MRF and hair results are received (~2-3 544 
weeks), study eligibility will be determined.  545 
Screening contingency plans. Those who cannot provide documentation of 546 
HIV status (~25%) will receive pre-test counseling and a point-of-care HIV test. Further, 547 
in past research ~30% of PLWH-NECTA could not provide a MRF because they did not 548 
have a regular health care provider [34]. In such cases, self-reported care engagement 549 
information will be accepted. If a hair sample cannot be obtained, a blood specimen will 550 
be obtained and HIV VL > 1000 pp/mL will serve as a reasonable proxy for ART status 551 
(i.e., not taking ART). 552 
Step 3: The Enrollment visit. This visit will entail written informed consent for 553 
remaining study activities, administering the baseline interview, obtaining a blood 554 
specimen for baseline CD4 and VL levels, randomizing the participant to an 555 
experimental condition, and scheduling the Core intervention session. Random 556 
assignment will be stratified by age (younger PLWH [18-35 years] vs. older PLWH [36-557 
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65 years]). The measures that comprise the structured baseline assessment are 558 
presented in Table 1.  559 
(insert Table 1. Assessment Instruments) 560 
 561 
Sequence of intervention components 562 
Some of the 16 conditions are intensive but delivery is feasible, based on our extensive 563 
experience with complex interventions. As Figure 2 shows, the majority of conditions 564 
have 3-4 components. Sequences of components will follow pre-established rules: the 565 
Core intervention is delivered first, MI counseling sessions (where assigned) will come 566 
second, components may be provided simultaneously in some cases but will be 567 
scheduled so they do not conflict, and pre-adherence preparation will be scheduled to 568 
start after a minimum of 1.5 months of navigation. All participants receive the core 569 
intervention and 3 or 6 months of navigation, with the intervention periods ranging from 570 
~3.25 to ~8 months. Participants receive modest compensation for intervention activities 571 
(e.g., $25 for a session, group, or other activity plus funds for two-way public 572 
transportation). 573 
 574 
Preventing contamination across experimental conditions 575 
There are two main forms of contamination that could arise in the present study if a 576 
participant learns what other components (and other forms of treatment) a fellow 577 
participant is receiving. One potential form of contamination would be “resentful 578 
demoralization;” that is, participants feeling disappointed or disgruntled by their 579 
treatment in the study relative to other participants, which could then possibly reduce 580 
their motivation to engage in the study [175]. A second concern would be that a 581 
participant would be triggered to pursue similar types of activities outside of the study to 582 
compensate for what is not being received in the study. There are two main places that 583 
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contamination could occur: in study waiting areas, and in the focused support group 584 
component, when participants from different experimental conditions come together. To 585 
prevent contamination from either the “waiting room” or support group component, 586 
participants will be informed at enrollment that that study involvement and compensation 587 
varies across participants, in order to manage expectations. Further, at enrollment we 588 
will ask that participants not discuss the specifics of study components with other 589 
participants. Then, within the context of the focus support groups, the facilitator will 590 
attend to and discourage discussion of other components by participants in the groups. 591 
We may not be able to eliminate contamination entirely, but we can takes steps to 592 
minimize it. 593 
 594 
Blinding 595 
To foster fidelity to the intervention manuals and maintain the integrity of each separate 596 
component, interventionists will each deliver only one type of component and be blind to 597 
participants’ condition assignments. For example, interventionists trained to provide 598 
navigation will not be trained in any other component, and will not deliver any other 599 
component.  600 
 601 
Intervention quality assurance 602 
We will establish and maintain treatment fidelity to the 16 Conditions and the core 603 
elements of each component. A REDCap database will be programmed to reflect the 604 
participant’s intervention assignments and will prompt interventionist action steps. After 605 
each contact, interventionists will complete fidelity checklists. Audiotaped sessions will 606 
be randomly selected and rated for treatment fidelity by independent raters using the MI 607 
Treatment Integrity (MITI) coding system. A clinical supervisor will review recordings of 608 
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group sessions. Interventionist fidelity will be reviewed in bi-monthly individual 609 
supervision meetings. 610 
 611 
Sample size 612 
A total of 512 participants will be enrolled in the experiment. For the primary outcome, 613 
HIV viral suppression at the final follow-up, we used PASS [176] to estimate the sample 614 
size needed for individual main effects of intervention components corresponding to 615 
odds ratios (OR) of 1.9 in logistic regression, given α=.05. A transition from viremia to 616 
viral suppression has clear clinical significance for individual patients, and the effect size 617 
reflects the need to have at least a moderate impact on the rate of suppression for public 618 
health impact. Assuming participants not receiving or receiving the lowest intensity of 619 
each component have a 20% chance of viral suppression at the final follow-up, a sample 620 
size of 404 provides 80% power to detect an OR of 1.9. To account for attrition of up to 621 
20% of enrolled participants, we propose a total sample size of 512 participants to 622 
ensure complete data for at least 404. Given the proposed sample size, when the main 623 
effect of an intervention component on a continuous measure of a secondary outcome 624 
(e.g., log10 VL) or mediator is estimated in a linear model or independent-samples t-test, 625 
the sample size provides 80% power to detect a small standardized mean difference (d 626 
= .28). Moderator effects corresponding to an odds ratio of OR=1 in one subgroup and 627 
OR=3 in another can be detected with 76% if subgroups sizes are roughly equal. 628 
 629 
Randomization and data management 630 
A secure, web-based, password-protected database built on a REDCap platform will be 631 
used to manage recruitment, eligibility assessment, randomization to the 16 632 
experimental conditions, scheduling and tracking, baseline and follow-up assessments, 633 
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and delivery of the intervention components (with cues, prompts, pull-down menus, 634 
Likert scales, and open ended responses).  635 
 636 
Collection of HIV care patterns using the Medical Report Form (MRF).  637 
We will obtain a MRF, a type of participant-facilitated chart review, at screening and the 638 
4- and 12-month follow-up assessments, by contacting the Medical Records Office or 639 
health care provider where the participant receives HIV primary care, or asking 640 
participants to have their providers complete a MRF. The MRF will be completed by the 641 
provider and faxed to us in a secure fax line in a locked office at the New York University 642 
Meyers College of Nursing. The MRF is very brief (solicits the number of missed and 643 
kept HIV care appointments), so as to not burden health care providers and facilities. In 644 
the event these data cannot be obtained for a participant, for example, because the 645 
participant does not have a primary care provider, such data on health care attendance 646 
patterns will be collected by self-report.  647 
 648 
Assessing ART adherence levels in hair 649 
Measuring ART exposure via hair is an objective and innovative biomarker of 650 
adherence. Average adherence to boosted protease inhibitors (PIs) is a better predictor 651 
of virologic suppression than duration or frequency of missed doses [177]. Further, hair 652 
levels of ART have been found to be stronger predictors of treatment outcomes than 653 
self-reported adherence [103, 178] or single plasma ART concentrations [178]. Dr. 654 
Monica Gandhi, a study collaborator, has developed methods to analyze protease 655 
inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), tenofovir (TFV), 656 
and emtricitabine (FTC) using liquid chromatography/ tandem mass spectrometry 657 
(LC/MS/MS) [103, 179-183]. PIs and NNRTIs require 20-30 strands of human hair (~1-3 658 
milligrams [mg]) and TFV or FTC from 50-100 strands of hair (~5-10 mg). These 659 
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methods have been validated with good linearity (R2>0.99) and reproducibility 660 
(coefficient of variation [CV]<15%) for all ART drugs. Moreover, many of the hair assays 661 
developed in our collaborating laboratory led by Dr. Gandhi have been peer-reviewed 662 
and approved by the NIAID Division of AIDS Clinical Pharmacology and Quality 663 
Assurance (CPQA) program [184, 185]. 664 
 665 
Hair collection is noninvasive and does not require specific skills, sterile equipment, or 666 
specialized storage conditions, and high rates of acceptability and feasibility of collecting 667 
hair samples for hair ART monitoring have been found in the Women’s Interagency HIV 668 
study (WIHS) [178, 186, 187]. In the present study, 100 strands of hair will be collected 669 
and assayed for TFV concentrations [180] in those on TFV-based regimens (a 670 
commonly-used agent in current regimens) [105]. For those not on TFV-based regimens, 671 
hair samples will be screened for the anchor antiretroviral (e.g. NNRTI, PI or integrase 672 
inhibitor). At follow-up, participants’ specific ART regimen will be logged from pill bottles 673 
or prescriptions, and hair analyses will be conducted for the relevant agents.  674 
 675 
Follow-up assessment schedule and activities 676 
The follow-up (FU) periods and assessment schedule (4-, 8, and 12- months post-677 
baseline) are based on the hypothesized timing and rate of change [188]. The FU 678 
schedule will allow assessment of the initiation of and adherence to ART, viral 679 
suppression, and patterns of engagement in care over time. Each FU includes a brief 680 
structured assessment battery (< 60 mins.); the 4-month FU also includes a blood draw 681 
(for VL), hair sample collection (if taking ART), and completion of a MRF (for 682 
assessment of HIV primary care visits) from participants’ HIV care site; the 8-month FU 683 
includes hair sample collection; and the 12-month FU includes a blood draw (CD4, VL), 684 
hair sample collection, and MRF. Specific reliable/valid assessment instruments for each 685 
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mediator are presented in Table 1, as well as to assess socio-demographic and 686 
background characteristics. Time, resources, and cost of delivering each intervention 687 
component will be collected using forms created by the Drug Abuse Treatment Cost 688 
Analysis Program [189]. Participants receive modest compensation for assessments 689 
($25), providing hair samples ($10), and blood specimens ($20), plus funds for two-way 690 
public transportation. 691 
 692 
Qualitative interviews and data integration 693 
To add context and richness to our understanding of participants’ experiences with 694 
intervention components, advance understanding of barriers to care/ART, and inform 695 
future research, we will embed qualitative interviews into the study. A subset of 696 
participants will be purposively selected for maximum variation for qualitative interviews 697 
[190]. We will enroll N=40 total, or until saturation on core constructs is reached [191]. 698 
Interviews will follow a semi-structured guide with a “start list” of key questions drawn 699 
from the theoretical model domains, and also allow for exploration of unanticipated 700 
themes. The use of the start list fosters data integration across qualitative and 701 
quantitative data sets, because the same core constructs are assessed in each. 702 
Analyses will be conducted by two qualitative researchers using Dedoose (a platform for 703 
mixed methods analysis). Participants receive modest compensation for the qualitative 704 
interview ($25), plus funds for two-way public transportation. 705 
 706 
Statistical methods 707 
Intent-to-treat analysis will be our primary analytic approach and exploratory analyses 708 
will examine complier average effects of intervention components [192, 193]. 709 
Approaches to missing data will include full information maximum likelihood estimation 710 
[194] and multiple imputation [190]. In sensitivity analysis, missing data will be treated as 711 
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failure to achieve the desired outcome. If data are missing not at random (MNAR), we 712 
will employ sensitivity analysis, using selection [107] or pattern mixture [195, 196] 713 
models. 714 
 715 
Aim 1: Identify which of five components contribute meaningfully to improvement in the 716 
primary outcome, HIV viral suppression, as well as, absolute HIV viral load; ART 717 
adherence levels; and engagement in HIV care. 718 
 719 
The primary outcome for Aim 1 is viral suppression at the final follow-up point (12-720 
months post-baseline). Logistic regression will be used to estimate effects of 721 
components on the odds of viral suppression. Experimental factors will be effect coded 722 
to estimate main effects and two-way interactions of all five intervention components. 723 
The coefficient for a main effect term, multiplied by two and exponentiated, will estimate 724 
the effect of the component on the odds of viral suppression. Similarly, the coefficient for 725 
an interaction term, multiplied by two and exponentiated, will estimate interaction effects 726 
between intervention components on the odds of viral suppression. Similar logistic 727 
regression analyses will estimate effects of components on secondary outcomes. Linear 728 
regression will estimate effects of components on VL (after log10 transformation) and 729 
ART concentration in hair samples. 730 
 731 
Relationships among participants. The sampling and intervention design may 732 
create clusters of participants whose outcomes are not fully independent. Participants 733 
with recruitment relationships may have more similar outcomes than two randomly 734 
selected participants. Also, participants receiving an intervention activity together may 735 
have more similar outcomes than randomly selected participants. Intraclass correlations 736 
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or median ORs [197] will be estimated, and the impact of design effects on inferences 737 
will be considered. 738 
 739 
Aim 2: Identify mediators and moderators of the efficacy of each intervention 740 
component. 741 
 742 
Generalized linear model analysis will determine impacts of intervention components on 743 
mediators. MacKinnon and Dwyer [198] and MacKinnon [199] discuss how mediated 744 
effects can be calculated when the outcome or mediator variable is categorical. Probit 745 
regression, used to estimate indirect effects, will determine which mediators are related 746 
to viral suppression, after controlling for intervention components received. Intervention 747 
components may not be equally effective for all participants. The following factors, and 748 
others, may modify the relation between the intervention and outcomes: age, gender, 749 
sexual minority status, and substance use. The examination of potential moderator 750 
effects will involve forming interaction terms using the procedures described by Aiken 751 
[200] and Jaccard [201] and estimating simple effects. MOST enables estimation of 752 
moderator effects for each intervention component and component two-way interactions. 753 
Substance use will be thoroughly characterized in structured assessments using mainly 754 
measures approved by National Institute on Drug Abuse (NIDA) for the “Seek, Test, 755 
Treat, and Retain” initiative data harmonization effort. Given past research, we anticipate 756 
most participants (~80%) will have lifetime drug use and approximately half will have 757 
recent substance use. Importantly, we anticipate variation in a number of salient aspects 758 
of substance use among substance users (e.g., quantity and frequency of use, 759 
consequences of use, duration of use) will allow us to consider important intervention 760 
effect moderators. Identified moderators will be used to inform future development of 761 
adaptive interventions [145]. 762 
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 763 
Aim 3: a) Using significance tests and effect size estimates obtained in Aim 1 analysis, 764 
identify components with efficacy, taking interactions into account; b) use modeling to 765 
estimate cost-effectiveness of possible packages composed of efficacious components; 766 
and c) identify the most cost-effective package. 767 
 768 
The selection of the combination of intervention components that will make up the new 769 
multi-component “optimized” intervention will proceed as follows [35-37]. First, based on 770 
the experimental results, ineffective components will be eliminated.  Components 771 
empirically demonstrated to be efficacious, and therefore candidates for inclusion in the 772 
optimized intervention, will be identified using procedures outlined in Collins et al. [37]. 773 
An initially selected component may be deselected if it interacts with another component 774 
in such a way as to undermine its effect, or a component not initially selected may be 775 
selected if it interacts with another component to enhance its effect. Then, drawing from 776 
the remaining components, the set of components/component levels that meets the 777 
optimization criterion, in this case cost-effectiveness, will be selected. Starting with effect 778 
sizes and costs of efficacious components, computer simulation methods will identify 779 
intervention packages that most increase population health for the magnitude of 780 
resources they consume (i.e., on the efficiency frontier of the cost-effectiveness plane). 781 
Enhancing our validated HIV simulation with new “states” (e.g., disengaged, 782 
engaged/not on ART, engaged/on ART but not adherent), we will consider downstream 783 
as well as immediate costs, and follow guidelines of the Panel on Cost-Effectiveness in 784 
Health in Medicine [202]. Utilities (preference-weighted quality-of-life measures used in 785 
cost-effectiveness analyses) will vary by CD4 count, and will be based on those used in 786 
the modeling analyses [203-208]. 787 
 788 
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Uncertainty and sensitivity analyses. We will perform a probabilistic sensitivity 789 
analysis in which all inputs are simultaneously varied across their plausible ranges, and 790 
assess the proportion of runs that an intervention strategy remains on the efficient 791 
frontier. We also will perform a sensitivity analysis by strength of evidence [209, 210], 792 
where we vary an evidence “filter” that only allows data sources to inform input 793 
assumptions if they pass through the “filter” and meet the minimum standard of 794 
evidence, thereby assessing the lowest level of evidence filter compatible with a 795 
particular intervention strategy remaining on the efficient frontier. 796 
 797 
Assumptions. We will make conservative assumptions about duration of effects, 798 
assuming they last only as long as the last observed follow-up, but will explore more 799 
optimistic assumptions in sensitivity analyses. We will base resource utilization not only 800 
on the costs of the intervention package itself, but also considering changes in 801 
attributable downstream costs (e.g. people re-linked to care might incur lower 802 
hospitalization expenses in the long-term because they maintain higher CD4 counts and 803 
are less likely to get AIDS). Relative trajectories of utilization pathways (drug costs, 804 
outpatient costs including labs and visits, and inpatient costs) with versus without re-805 
engagement in care will be estimated based on our simulation. We will perform analyses 806 
from different perspectives (societal and payer), time horizons (infinite, 20, 10, and 5-807 
year), and discount rates (5%, 3%, and 0%) but with base case assumptions in accord 808 
with established guidelines [203, 211-215]. 809 
 810 
Data monitoring 811 
We will perform reliability checks on measures at an interim analysis point. Construct 812 
validity of key measures will be assessed using measurement models within a structural 813 
equations format (using Mplus).  814 
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 815 
Fidelity, process ratings, and quality assurance 816 
As noted above, after each intervention session/navigation contact the interventionist will 817 
complete process ratings. These ratings will be used in regular supervision sessions to 818 
insure fidelity to the intervention manual. Sessions will be audiorecorded (if participants 819 
give their signed informed consent) and ~10% of the tapes selected at random will be 820 
reviewed for quality assurance and supervision purposes by an independent rater who 821 
will complete a standard process rating checklist. They will be reviewed within 822 
approximately a month of their taping to ensure timely feedback and then destroyed. The 823 
facilitators will attend monthly supervision meetings with a senior clinician where quality 824 
assurance, clinical issues, and intervention fidelity issues will be reviewed. The study will 825 
employ a number of procedures to address “drift” from intervention fidelity including on-826 
going supervision meetings with facilitators and senior staff, regular monitoring of 827 
process ratings, and “booster” training of facilitators based on the intervention manual 828 
provided as needed.  829 
 830 
Check on level of missing data and any patterns by item, data source, or staff 831 
person.  832 
We propose to use the SPSS Missing Values Analysis (MVA) program to identify 833 
possible non-random patterns of missing data. When items, data sources, or staff are 834 
associated with more than 10% missing data that are not due to planned interview skip 835 
patterns, we will determine the causes of missing data and implement strategies to 836 
reduce it (e.g., retraining of staff).  837 
 838 
Harms 839 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
34 
 
The study will make use of a Data Safety and Monitoring Board (DSMB). Several 840 
mechanisms will be put in place to monitor potentially adverse events that participants 841 
may experience while enrolled in the study, whether they are related to project 842 
participation or not. These events are classified as either Reportable, Adverse, or Not 843 
Harmful/Expectable, as described below, and will be reported to the New York University 844 
(NYU) and Pennsylvania State University Institutional Review Boards (IRBs), DSMB, 845 
and the sponsor’s Program Officer accordingly, as described below. Social harms will be 846 
assessed with a structured instrument at each FU point, and social harms may be 847 
reported during intervention activities. A Reportable Event is an unanticipated problem 848 
involving risks to participants or others (“Unanticipated Problem”) and any event or 849 
information that (1) was unforeseen and (2) indicates that the research procedures 850 
caused harm to participants or others or indicates that participants or others are at 851 
increased risk of harm. 852 
 853 
Research ethics approval 854 
The study protocol will be approved by the IRB of the New York University School of 855 
Medicine (the IRB of record), Pennsylvania State University (Dr. Linda Collins, Co-856 
Principal Investigator), and Binghamton University (Dr. Leo Wilton, Co-Investigator).  857 
 858 
Consent  859 
Verbal consent will be obtained and a structured pre-screening interview will be 860 
conducted to preliminarily screen for eligibility (criteria assessed by self-report).  Signed 861 
informed consent for the remaining screening procedures will be obtained. Those found 862 
eligible will provide signed informed consent to enroll in the study. Participants will 863 
provide separate signed consent to have the qualitative interviews and intervention 864 
sessions audio-recorded. Participants may decline to have their qualitative interviews or 865 
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intervention sessions recorded and still continue with the interviews or sessions. The 866 
voluntary nature of all study activities is emphasized in the consent forms. The 867 
participant will be provided a copy of the consent form that includes contact information 868 
for the research team members and the NYU IRB. Participants can use this contact 869 
information to report adverse events or unanticipated problems. 870 
 871 
Confidentiality 872 
All participants will receive a Participant Identification Number (PID) that will be used for 873 
all interviews, forms, materials, hair samples, blood specimens, transcripts, and 874 
intervention materials. No other information that would disclose the participant’s identity 875 
will be found on any interview or form. Paper forms will be kept without serostatus 876 
identification in locked cabinets at NYU. Only the consent form, locator form and a 877 
Master Participant Log File will link the participant’s name to the identification number. 878 
Staff receives training about confidentiality and the New York State HIV Confidentiality 879 
Law. Participants will provide verbal informed consent for the brief screening interview, 880 
and for those found preliminarily eligible, signed informed consent for remaining study 881 
activities (assessments, blood specimens, hair samples, intervention, peer recruitment). 882 
 883 
Discussion 884 
 885 
The goal of elimination of HIV transmission in the United States will not be achieved 886 
without improvements in engagement along the HIV care continuum. The present study 887 
targets the large population of PLWH in the United States who are both insufficiently 888 
engaged in HIV primary care and not taking ART, who are mainly African 889 
American/Black and Hispanic. The National Institutes of Health has emphasized the 890 
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urgent need for new research approaches to advance intervention science, and the 891 
proposed project employs a new, potent, and innovative research methodology, the 892 
multiphase optimization strategy (MOST), a framework for developing highly efficacious, 893 
efficient, scalable, and cost-effective interventions. The proposed study has the highest 894 
public health significance: it addresses a vulnerable population of PLWH, including the 895 
critically important subpopulations of MSM and substance users; will develop an efficient 896 
and cost-effective intervention to increase engagement along the HIV care continuum for 897 
these vulnerable groups; and addresses two research priorities areas from the National 898 
Institutes of Health Office of AIDS Research (NOT-OD-15-137), namely, engaging 899 
PLWH in prevention/treatment services, and reducing HIV/AIDS-related racial/ethnic 900 
disparities.  901 
 902 
 903 
 904 
Abbreviations: 905 
AABH-PLWH: African American/Black and Hispanic persons living with HIV 906 
ART: Antiretroviral therapy 907 
CAB: Community Advisory Board 908 
CPQA: Clinical Pharmacology and Quality Assurance 909 
CV: Coefficient of variation 910 
DSMB: Data Safety and Monitoring Board 911 
FTC: Emtricitabine 912 
FU: Follow-up 913 
HIPAA: Health Insurance Portability and Accountability Act 914 
HRSA: Human Resources and Services Administration 915 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
37 
 
HTH: Heart to Heart Study 916 
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Table 1. Assessment instruments   
PROXIMAL MEDIATORS (to assess each intervention component) 
Health beliefs (i.e., outcome expectancies, 
care/ART necessity, distrust) and emotions 
(i.e., fear)  
 Outcome expectancies re: care and ART (9 items each; α = .93) [158] 
 Care and ART Necessity scale (10 items each; α = .80) [159] 
 HIV and ART distrust (10 items; α = .84); HIV health care provider distrust (11 
items; α = .88); General medical distrust (7 items; α = .72) [160-162] 
 Care & ART Concerns & Fears subscale (disclosure, side effects; 13 items; α = 
.80) [56, 159] 
Adherence behavioral skills  Mean % adherence rating from up to 4 one-week trial periods via MEMS caps; 
HIV Medication Readiness Scale (10 items; α = .90) [163] 
Peer Models and peer norms regarding HIV 
care and ART 
 Peer models (number and quality of “successful” HIV+ peers in care, on ART; α 
= .90) [164] 
 Subjective peer norms for HIV care and ART (6 items each; α = .84) [165] 
Social support and stigma associated with 
care, ART 
 Social support (α = .88) [166] 
 Stigma associated with taking or not taking HIV care and ART (3 items each; α 
= .73) [167] 
Structural barriers to care/ART  HIV-related structural/ practical barriers to care, ART (α = .72) [136] 
DISTAL MEDIATORS 
 Motivation and readiness for care and ART [168] 
 Schedule of HIV appointments [169] 
 ART Prescription [169] 
 Ancillary treatment [170] 
 Substance use frequency [171] 
 Depression [172] 
MODERATORS 
 Socio-demographic characteristics (age, biological sex, sexual minority status, 
race/ethnicity) 
 HIV history and ART history 
 Substance use [171] 
 Depression [172] 
 Anxiety 
OTHER DESCRIPTIVE AND 
BACKGROUND VARIABLES 
Housing status, transgender identity, employment status, health status; where 
receives HIV care, incarceration; sex work history; reasons not on ART or 
discontinued ART; ART side effects (at FU); HIV treatment knowledge [173]; 
Methadone Maintenance; satisfaction with HIV care [174] 
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Figure 1. Click here to download Figure Figure 1 Conceptual model.PNG 
Figure 2. Click here to download Figure Figure 2 Conditions in the
fractional factorial design.PNG
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Peer recruitment opportunities
Second Screen for Eligibility
Written informed consent
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Document HIV status, care status (MRF)
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Enrollment Visit
Written informed consent
Baseline interview
Baseline blood draw (CD4, VL)
Randomization 
HTH2 Intervention (3-8 mos)
Core session
A) MI counseling session (Yes/ No)
B) Pre-adherence preparation (Yes/ No)
C) Peer mentorship (Yes/ No)
D) Support groups (Yes/ No)
E) Navigation (3 mos/ 6 mos)
Follow-Up Period
Structured Assessments @ 4-, 8-, 12-mos post-baseline
Hair sample @ 4-, 8-, 12-mos
Medical Report Forms @ 4- and 12-mos
Blood draw @ 4-mos for VL
Blood draw @ 12-mos for VL and CD4
Qualitative Interview
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